Insilico picks AI-designed GIPR blocker for next obesity drug
The AI drug developer nominated ISM1354 for obesity, and says early lab and animal data point to better exposure and a wider safety margin. At the same dose, one of Insilico Medicine’s new molecules delivered at least 18 times more drug into the bloodstream than a clinical-stage comparison compound.
<p>The AI drug developer nominated ISM1354 for obesity, and says early lab and animal data point to better exposure and a wider safety margin. At the same dose, one of Insilico Medicine’s new molecules delivered at least 18 times more drug into the bloodstream than a clinical-stage comparison compound.</p>